HRYZ TP01
Alternative Names: HRYZ-TP01Latest Information Update: 02 Aug 2024
At a glance
- Originator HengRui YuanZheng Bio-Technology
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Liver cancer
Most Recent Events
- 17 Jul 2024 HRYZ TP01 is available for licensing as of 31 Dec 2024. http://www.shhryz.com/Web/About/Index?id=68 (HengRui YuanZheng Bio-Technology pipeline, July 2024)
- 17 Jul 2024 Early research in Liver cancer in China (Parenteral) prior to July 2024 (HengRui YuanZheng Bio-Technology pipeline, July 2024)